Netflix Stock Slips as Subscriber Slowdown and Rising Churn Spark Investor Concerns
Netflix stock falls as subscriber growth slows and cancellations rise. Ads help, but outlook weak and analysts stay cautious.
/ 220 items
#andre↓
Profit-Taking Hits Moderna Stock After mRNA-1010 Wins Unanimous FDA Panel Backing
Decision due Aug 5, 2026. Potential 2026–27 launch.
EB613 Set to Become First Once-Daily Oral Tablet for Osteoporosis as Entera Bio Advances to Phase 3
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
DeepMind Talent Exodus Hits Alphabet: Nobel Winner John Jumper Joins Anthropic
Another major exit follows Noam Shazeer’s move to OpenAI.
No Efficacy or Safety Issues: Achieve Life Sciences Gets FDA CRL for Cytisinicline
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
Breakthrough LSD-Derived Drug DT120 Shows Dramatic Antidepressant Effect in Phase 3 Trial
Definium’s DT120 pill showed strong fast and lasting depression relief in Phase 3, with good safety and big symptom cuts.